Výsledky vyhledávání - "I. González-Άlvaro"

AB0229 Does expression level of vip and its receptors correlated with disease severity in early arthritis?

Autor: A Seoane, M Carriόn, Rosa P. Gomariz, I. González-Άlvaro, Rosario García-Vicuña, A. Lamana, Yasmina Juarranz, Carmen Martínez

Publikováno v: Abstracts Accepted for Publication.

Background Rheumatoid Arthritis (RA) is a heterogeneous disease, not only in the course but also in the response to treatment (1). So, a major challenge is the classification of patients according to the disease severity/mildness to apply customized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d7dea310f8824a661a668d76f7f9b32
https://doi.org/10.1136/annrheumdis-2017-eular.4817

Zobrazit plný text záznamu

FRI0016 Involvement of runx-2 and β-catenin signaling in the production of adamts-7 and adamts-12 in osteoarthritic synovial fibroblasts

Autor: Rosa P. Gomariz, Irene Gutiérrez-Cañas, Yasmina Juarranz, Javier Leceta, Selene Pérez-García, I. González-Άlvaro, J Fernández, Raúl Villanueva-Romero

Publikováno v: Poster Presentations.

Background Proteinases released from synovial membrane of osteoarthritis (OA) patients contribute to cartilage damage. We recently reported in synovial fibroblasts (SF) the expression of ADAMTS (a disintegrin and metalloproteinase domain with thrombo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2390ce0d37164db936717af340419c4f
https://doi.org/10.1136/annrheumdis-2017-eular.5808

Zobrazit plný text záznamu

AB0033 B Cell Depletion by Rituximab in Lymphocyte Subpopupulations from Peripheral Blood in Patients with Rheumatoid Arthritis

Autor: J. Lόpez Lόpez, C. Muñoz-Calleja, S. Castañeda Sanz, Rosario García-Vicuña, I. Llorente, José María Álvaro-Gracia, L. Merino Meléndez, F. Herrera, I. González-Άlvaro, T. Velasco

Publikováno v: Annals of the Rheumatic Diseases. 74:901.2-901

Background Rheumatoid arthritis (RA) is a chronic disease that leads to inflammation of the joints and other tissues. Rituximab (Rtx) is a therapeutic monoclonal antibody directed against CD20 that induces an important depletion of B cells. Although

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14b0fd894748f1e59ff3cfaf6699ddba
https://doi.org/10.1136/annrheumdis-2015-eular.5447

Zobrazit plný text záznamu

AB0272 Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients

Autor: Ana M. Ortiz, L. Merino, R. Garcia de Vicuna, Esther Vicente, Teresa Velasco, I. Llorente Cubas, I. González-Άlvaro, E. García Lorenzo, A. García-Vadillo, Eugenio Escolano, Santos Castañeda

Publikováno v: Annals of the Rheumatic Diseases. 74:982.3-983

Background Recently it has been described that anti citrullinated protein antibodies (ACPA) can induce differentation and activation of osteoclasts even before arthritis onset (1,2). Objectives The aim of this study was to analyze the effect of ACPA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::361f34880082416559917e45e72225c5
https://doi.org/10.1136/annrheumdis-2015-eular.5571

Zobrazit plný text záznamu

AB0418 Is There A Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab When IT is Used with A Fixed Pattern Every Six Months or On-Demand? A Systematic Review

Autor: Alfredo Ortiz, M.P. Rosario Lozano, I. González-Άlvaro, C. Martínez Fernández

Publikováno v: Annals of the Rheumatic Diseases. 73:945.2-945

Background Since the description of the efficacy of rituximab (RTX) in treating patients with rheumatoid arthritis (RA), the use of this drug has been extended. Nevertheless, there are not clearly established guidelines to follow after administration

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1f026e9b1b100013466cbc9de18e3f63
https://doi.org/10.1136/annrheumdis-2014-eular.4005

Zobrazit plný text záznamu

AB0107 The Expression of VIP Receptors, VPAC1 and Vpac2, is Related to Disease Activity in Patients with Early Arthritis

Autor: A. Lamana, I. González-Άlvaro, Yasmina Juarranz, Javier Leceta, L. Piris, Carmen Martínez, Iria V. Seoane, Rosa P. Gomariz, Ana M. Ortiz

Publikováno v: Annals of the Rheumatic Diseases. 73:839.2-839

Background The vasoactive intestinal peptide (VIP) and its two receptors (VPAC1 and VPAC2) mediate critical cellular functions in the regulation of innate and adaptive immune response as has been confirmed in animal models and in vitro. These recepto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55a9ab0210535a8207818819b35df5ab
https://doi.org/10.1136/annrheumdis-2014-eular.3472

Zobrazit plný text záznamu

SAT0225 Is There A Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab When Using A Dose of 1 or 2 Grams per Cycle? A Systematic Review

Autor: I. González-Άlvaro, C. Martínez Fernández, M.P. Rosario Lozano, Alfredo Ortiz

Publikováno v: Annals of the Rheumatic Diseases. 73:671.3-672

Background Since the description of the efficacy of rituximab (RTX) in treating patients with rheumatoid arthritis (RA), the use of this drug has been extended. The recommendation in fact sheet is the administration of two infusions of 1 g in each cy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed3689645c11bea267b560689e7505bc
https://doi.org/10.1136/annrheumdis-2014-eular.4004

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání